title: Plasma apolipoprotein M responses to statin and fibrate administration in type 2 diabetes mellitus.
abstract: OBJECTIVE
  Plasma apolipoprotein M (apoM) is potentially anti-atherogenic, and has been found to be associated positively with plasma total, LDL and HDL cholesterol in humans. ApoM may, therefore, be intricately related to cholesterol metabolism. Here, we determined whether plasma apoM is affected by statin or fibrate administration in patients with diabetes mellitus.
  
  
  METHODS
  Fourteen type 2 diabetic patients participated in a placebo-controlled crossover study which included three 8-week treatment periods with simvastatin (40 mg daily), bezafibrate (400 mg daily), and their combination.
  
  
  RESULTS
  ApoM was decreased by 7% in response to simvastatin (P<0.05 from baseline and placebo), and remained unchanged during bezafibrate and combined simvastatin+bezafibrate administration. Plasma apoM concentrations correlated positively with apoB-containing lipoprotein measures at baseline and during placebo (P<0.02 to P<0.001), but these relationships were lost during all lipid lowering treatment periods.
  
  
  CONCLUSIONS
  This study suggests that, even though plasma apoM is lowered by statins, apoM metabolism is to a considerable extent independent of statin- and fibrate-affected pathways involved in cholesterol homeostasis.
authors.affiliation: Department of Endocrinology, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands.
authors.forename: Paul J W H
authors.initials: PJ
authors.lastname: Kappelle
authors.forename: Josefin
authors.initials: J
authors.lastname: Ahnström
authors.forename: Bert D
authors.initials: BD
authors.lastname: Dikkeschei
authors.forename: Rindert
authors.initials: R
authors.lastname: de Vries
authors.forename: Wim J
authors.initials: WJ
authors.lastname: Sluiter
authors.forename: Bruce H R
authors.initials: BH
authors.lastname: Wolffenbuttel
authors.forename: Arie
authors.initials: A
authors.lastname: van Tol
authors.forename: Lars Bo
authors.initials: LB
authors.lastname: Nielsen
authors.forename: Björn
authors.initials: B
authors.lastname: Dahlbäck
authors.forename: Robin P F
authors.initials: RP
authors.lastname: Dullaart
mesh_terms: D001053:Apolipoproteins / Q000097:blood*; D000075243:Apolipoproteins M; D001629:Bezafibrate / Q000627:therapeutic use; D001794:Blood Pressure; D002784:Cholesterol / Q000378:metabolism; D018592:Cross-Over Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*; D004311:Double-Blind Method; D058607:Fibric Acids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000378:metabolism*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D054834:Lipocalins; D008297:Male; D008875:Middle Aged; D010919:Placebos; D019821:Simvastatin / Q000627:therapeutic use
chemical_list: C400523:APOM protein, human; D001053:Apolipoproteins; D000075243:Apolipoproteins M; D058607:Fibric Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D054834:Lipocalins; D010919:Placebos; D002784:Cholesterol; D019821:Simvastatin; D001629:Bezafibrate